口腔黏膜恶性黑色素瘤肺转移特征及预后分析

doi:10.19401/j.cnki.1007-3639.2022.12.006

中国癌症杂志 ›› 2022, Vol. 32 ›› Issue (12): 1184-1189.doi: 10.19401/j.cnki.1007-3639.2022.12.006

口腔黏膜恶性黑色素瘤肺转移特征及预后分析

韩如雪¹^,², 梁翔³, 马旭辉², 郭伟², 吴云腾², 任国欣¹^,²

1.潍坊医学院口腔医学院，山东潍坊 261000
2.上海交通大学医学院附属第九人民医院，口腔颌面-头颈肿瘤科，上海交通大学口腔医学院，国家口腔医学中心，国家口腔疾病临床医学研究中心，上海市口腔医学重点实验室，上海 200011
3.上海交通大学医学院附属第九人民医院胸外科，上海 200011

收稿日期:2022-07-24 修回日期:2022-12-24 出版日期:2022-12-30 发布日期:2023-02-02
通信作者: 任国欣
作者简介:韩如雪。

Characteristics and prognostic analysis of oral mucosal melanoma with lung metastasis

HAN Ruxue¹^,², LIANG Xiang³, MA Xuhui², GUO Wei², WU Yunteng², REN Guoxin¹^,²

1. School of Stomatology, Weifang Medical University, Weifang 261000, Shandong Province, China
2. Department of Oral & Maxillofacial-Head and Neck Oncology, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, College of Stomatology, Shanghai Jiao Tong University, National Center for Stomatology, National Clinical Research Center for Oral Diseases, Shanghai Key Laboratory of Stomatology, Shanghai 200011, China
3. Department of Thoracic Surgery, Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China

Received:2022-07-24 Revised:2022-12-24 Published:2022-12-30 Online:2023-02-02
Contact: REN Guoxin

摘要/Abstract

摘要：

背景与目的：口腔黏膜恶性黑色素瘤（oral mucosal melanoma，OMM）是一类高度恶性的实体肿瘤，其远处转移率约40%，其中肺是最常见的远处转移部位；本研究旨在探讨OMM肺转移特征及预后影响因素，以期找到肺转移OMM最佳的治疗模式。方法：回顾性分析2017年1月—2021年1月于上海交通大学医学院附属第九人民医院确诊的肺转移OMM病例，总结胸部计算机体层成像（computed tomography，CT）的影像学特征，采用Kaplan-Meier方法进行生存分析。结果：88%的OMM患者在术后2年内确诊肺转移，其中第1年22例（52%），第2年15例（36%）；71%的患者胸部CT表现为大小不一、多发、圆形或椭圆形结节，寡转移少见（10%）；不按期随访（P = 0.009）、合并局部复发（P = 0.037）、合并胸腔积液（P = 0.042）以及未行免疫治疗（P = 0.000）会显著缩短患者的生存期。合并复发的患者对程序性死亡[蛋白]-1（programmed death-1，PD-1）免疫治疗的应答显著降低（P = 0.009），PD-1单药治疗的中位生存期只有10个月，联合抗血管靶向药物后中位生存期可延长至19个月（P=0.019）。结论： OMM易发生肺转移，即使小于1 cm的微小结节也可以发生转移灶。OMM转移最常发生在术后1~2年内，定期随访一定程度上能及早发现转移病灶从而延长患者的生存期。既复发又转移的OMM患者接受单纯免疫治疗往往效果欠佳，联合抗血管靶向治疗也许会有更好的治疗结局。

关键词: 口腔, 黏膜黑色素瘤, 肺转移, 复发, 随访

Abstract:

Background and purpose: Oral mucosal malignant melanoma (OMM) is a highly malignant solid tumor with a distant metastasis rate of about 40%. The lung is the most common metastatic site. This study aimed to investigate the characteristics and prognostic analysis of OMM with lung metastasis, in order to find the best treatment mode for OMM with lung metastasis. Methods: The data of the patients with lung metastasis diagnosed in the Ninth People’s Hospital Affiliated to the Medical College of Shanghai Jiao Tong University from January 2017 to January 2021 were retrospectively analyzed. The imaging characteristics of chest computed tomography (CT) were summarized, and Kaplan-Meier method was used for survival analysis. Results: In this study, 88% of patients with OMM were diagnosed with lung metastasis within 2 years after operation, including 22 cases (52%) in the first year and 15 cases (36%) in the second year; 71% of patients showed multiple, round or oval nodules of different sizes on chest CT, and few single metastases (10%). Non-scheduled follow-up (P = 0.009), concurrent local recurrence (P = 0.037), concurrent pleural effusion (P = 0.042) and no immunotherapy (P = 0.000) could significantly reduce the survival time of patients. The response of patients with relapse to programmed death-1 (PD-1) immunotherapy was significantly reduced (P = 0.009), and the median overall survival (OS) of PD-1 single drug was only 10 months. After combination therapy with PD-1 and anti-vascular targeted drugs, the median OS could be increased to about 19 months (P = 0.019). Conclusion: OMM is prone to lung metastasis, and even tiny nodules less than 1cm can be metastatic foci. The metastasis of OMM most often occurs within 1-2 years after operation. Regular follow-up can detect early metastasis and significantly prolong the survival. The efficacy of immunotherapy alone for recurrent and metastatic OMM is also poor, and immunotherapy combined with anti-vascular targeted therapy is required.

Key words: Oral, Mucosal melanoma, Lung metastasis, Relapse, Follow-up

中图分类号:

R739.8

韩如雪, 梁翔, 马旭辉, 郭伟, 吴云腾, 任国欣. 口腔黏膜恶性黑色素瘤肺转移特征及预后分析[J]. 中国癌症杂志, 2022, 32(12): 1184-1189.

HAN Ruxue, LIANG Xiang, MA Xuhui, GUO Wei, WU Yunteng, REN Guoxin. Characteristics and prognostic analysis of oral mucosal melanoma with lung metastasis[J]. China Oncology, 2022, 32(12): 1184-1189.

图/表 5

图1

图2

表1

图3

图4

参考文献 17

[1]	SUN C Z, LI Q L, HU Z D, et al. Treatment and prognosis in sinonasal mucosal melanoma: a retrospective analysis of 65 patients from a single cancer center[J]. Head Neck, 2014, 36(5): 675-681. doi: 10.1002/hed.23355
[2]	ASCIERTO P A, ACCORONA R, BOTTI G, et al. Mucosal melanoma of the head and neck[J]. Crit Rev Oncol Hematol, 2017, 112: 136-152. doi: S1040-8428(17)30045-8 pmid: 28325255
[3]	CHENG Y F, LAI C C, HO C Y, et al. Toward a better understanding of sinonasal mucosal melanoma: clinical review of 23 cases[J]. J Chin Med Assoc, 2007, 70(1): 24-29. doi: 10.1016/S1726-4901(09)70296-5
[4]	FAURE M, ROCHIGNEUX P, OLIVE D, et al. Hyperprogressive disease in anorectal melanoma treated by PD-1 inhibitors[J]. Front Immunol, 2018, 9: 797. doi: 10.3389/fimmu.2018.00797 pmid: 29725330
[5]	SUN S, HUANG X, GAO L, et al. Long-term treatment outcomes and prognosis of mucosal melanoma of the head and neck: 161 cases from a single institution[J]. Oral Oncol, 2017, 74: 115. doi: S1368-8375(17)30298-1 pmid: 29103739
[6]	MA X H, WU Y T, ZHANG T, et al. Ki67 proliferation index as a histopathological predictive and prognostic parameter of oral mucosal melanoma in patients without distant metastases[J]. J Cancer, 2017, 8(18): 3828-3837. doi: 10.7150/jca.20935 pmid: 29151970
[7]	GRÖZINGER G, MANN S, MEHRA T, et al. Metastatic patterns and metastatic sites in mucosal melanoma: a retrospective study[J]. Eur Radiol, 2016, 26(6): 1826-1834. doi: 10.1007/s00330-015-3992-9 pmid: 26373757
[8]	梁翔, 吴云腾. 伴复发转移的口腔黏膜黑色素瘤长期生存患者的临床特征及预后分析[J]. 中国癌症杂志, 2020, 30(7): 531-537.
	LIANG X, WU Y T. Clinical characteristics and prognosis of long-term survivors of oral mucosal melanoma with recurrence and metastasis[J]. China Oncol, 2020, 30(7): 531-537.
[9]	吴云腾, 任国欣, 孙沫逸, 等. 中国头颈黏膜黑色素瘤临床诊治专家共识[J]. 中国口腔颌面外科杂志, 2015, 13(3): 262-269.
	WU Y T, REN G X, SUN M Y, et al. Chinese expert consensus document on head and neck mucosal malignant melanoma[J]. China J Oral Maxillofac Surg, 2015, 13(3): 262-269.
[10]	SUN S R, HUANG X D, GAO L, et al. Long-term treatment outcomes and prognosis of mucosal melanoma of the head and neck: 161 cases from a single institution[J]. Oral Oncol, 2017, 74: 115-122. doi: S1368-8375(17)30298-1 pmid: 29103739
[11]	SAMSTEIN R M, CARVAJAL R D, POSTOW M A, et al. Localized sinonasal mucosal melanoma: outcomes and associations with stage, radiotherapy, and positron emission tomography response[J]. Head Neck, 2016, 38(9): 1310-1317. doi: 10.1002/hed.24435
[12]	GANTALA R, JANGILI U, KATNE T, et al. Oral mucosal melanoma: a case report[J]. J Indian Acad Oral Med Radiol, 2017, 29(1): 39. doi: 10.4103/jiaomr.JIAOMR_140_16
[13]	OWEN C N, SHOUSHTARI A N, CHAUHAN D, et al. Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy[J]. Ann Oncol, 2020, 31(8): 1075-1082. doi: S0923-7534(20)39788-X pmid: 32387454
[14]	COCOROCCHIO E, PALA L, CONFORTI F, et al. Successful treatment with avapritinib in patient with mucosal metastatic melanoma[J]. Ther Adv Med Oncol, 2020, 12: 1758835920946158.
[15]	ZIMMER L, LIVINGSTONE E, HASSEL J C, et al. Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage Ⅳ melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial[J]. Lancet, 2020, 395(10236): 1558-1568. doi: 10.1016/S0140-6736(20)30417-7
[16]	SHENG X, YAN X, CHI Z, et al. Axitinib in combination with toripalimab, a humanized immunoglobulin G4 monoclonal antibody against programmed cell death-1, in patients with metastatic mucosal melanoma: an open-label phase ⅠB trial[J]. J Clin Oncol, 2019, 37(32): 2987-2999. doi: 10.1200/JCO.19.00210
[17]	CHAE Y S, LEE J Y, LEE J W, et al. Survival of oral mucosal melanoma according to treatment, tumour resection margin, and metastases[J]. Br J Oral Maxillofac Surg, 2020, 58(9): 1097-1102. doi: 10.1016/j.bjoms.2020.05.028 pmid: 32586691

Variable	Case n	Median OS t/month	P value
Gender			0.991
Male	23	14.3±2.3
Female	19	16.8±3.4
Age/year			0.288
<50	17	15.6±3.6
≥50	25	15.3±2.3
Clinical stage			0.075
Ⅲ	12	23.5±5.0
Ⅳ	30	13.0±2.0
Regular follow-up			0.009
Yes	14	24.8±3.6
No	28	11.3±2.0
Local recurrence			0.037
Yes	30	12.6±1.9
No	12	25.2±5.2
Maximum diameter of nodule/cm			0.295
<2	24	18.4±3.6
≥2	46	14.1±2.5
Pleural effusion			0.042
Yes	6	7.2±1.4
No	36	17.6±2.5
Extrapulmonary metastasis			0.751
Yes	8	17.4±5.8
No	34	15.1±2.1
Therapies			0.000
Chemotherapy alone	13	4.6±0.3
Combined immunotherapy	29	19.9±2.6

口腔黏膜恶性黑色素瘤肺转移特征及预后分析

Characteristics and prognostic analysis of oral mucosal melanoma with lung metastasis

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

图/表 5

参考文献 17

相关文章 15

编辑推荐

Metrics

本文评价

[1]	唐多才, 周术奎, 张桂银, 刘磊, 廖洪. 非肌层浸润性膀胱癌行初次经尿道膀胱肿瘤电切术的术后复发危险因素分析[J]. 中国癌症杂志, 2023, 33(5): 478-483.
[2]	王笑笑, 陈曦, 李敏敏, 宋宁, 孙冬瑗, 蒋英英. NOL8对口腔鳞状细胞癌细胞增殖、迁移及侵袭的影响[J]. 中国癌症杂志, 2023, 33(1): 45-53.
[3]	曹孟轩, 胡灿, 张延强, 黄灵, 杜义安, 于鹏程, 章若岚, 徐志远, 程向东. 胃癌根治术后早期复发转移的危险因素分析[J]. 中国癌症杂志, 2022, 32(7): 588-595.
[4]	李婷, 徐宇, 贾东东, 廖智超, 孙伟, 吴海啸, 任志午, 赵军, 邢汝维, 滕胜, 杨蕴, 陈勇, 李涛, 杨吉龙. Ⅲ期恶性黑色素瘤患者术后辅助抗PD-1 vs 靶向治疗：中国多中心真实世界数据分析[J]. 中国癌症杂志, 2022, 32(12): 1147-1157.
[5]	赵明明, 王天佑, 王超. 妇科恶性肿瘤术后激素替代治疗的研究进展[J]. 中国癌症杂志, 2022, 32(11): 1098-1104.
[6]	林艺, 王策, 康勋, 康庄, 陈峰, 江波, 李文斌. 胶质母细胞瘤复发相关基因的筛选、表达和临床预后分析[J]. 中国癌症杂志, 2022, 32(1): 13-23.
[7]	蔡树模, 汤　洁, 黄　啸, 黄晓炜, 刘素萍, 柯桂好, 郑　重, 程　玺, 唐美琴. 铂类药物敏感复发卵巢癌患者的三步化疗法附20例分析[J]. 中国癌症杂志, 2021, 31(4): 330-334.
[8]	李　磊, 王　智, 由春媛 . 原发性心脏高级别B细胞淋巴瘤化疗缓解后复发1例报告[J]. 中国癌症杂志, 2021, 31(2): 156-160.
[9]	郭　晔, 张陈平 . 抗EGFR单抗治疗复发/转移性头颈部鳞状细胞癌临床共识（2021年版）[J]. 中国癌症杂志, 2021, 31(12): 1220-1232.
[10]	李　曾, 吴　毅, 程祝忠, 陈　丽, 廖　洪, 毛　顿, 肖英明, 谢洪平, 李秀丽, 杨盛柯, 周术奎, 钟　磊, 陆　皓, 陈勇吉 . ¹⁸ F-PSMA-1007 PET/CT对前列腺癌根治术后生化复发患者早期诊断评估和临床治疗决策影响的价值研究[J]. 中国癌症杂志, 2021, 31(11): 1081-1087.
[11]	樊　博, 齐　盼, 苏建志, 卫书飞, 张　轩, 张爱莉 . 河北医科大学第四医院前列腺癌患者的基线特征与生存分析[J]. 中国癌症杂志, 2020, 30(8): 620-625.
[12]	鲁晓腾, 许　青. 基于CT影像特征的非小细胞肺癌复发相关性因素研究[J]. 中国癌症杂志, 2020, 30(8): 636-640.
[13]	陈　阳 , 刘　伟 , 李瑞敏 , 王奇峰 , 沈茜刚 , 汤　伟 . 乳腺X线摄影影像学特征与21基因检测复发风险评分的相关性影像基因组学研究[J]. 中国癌症杂志, 2020, 30(7): 505-511.
[14]	梁　翔 , 吴云腾 . 伴复发转移的口腔黏膜黑色素瘤长期生存患者的临床特征及预后分析[J]. 中国癌症杂志, 2020, 30(7): 531-537.
[15]	冯　征, 吴小华　. PARP抑制剂用于铂敏感复发卵巢癌患者维持治疗的血液学毒性概述[J]. 中国癌症杂志, 2020, 30(4): 299-304.